Derek Tancredi
March 2026
Market Access Creative
Market access has never been static but in recent years, it has transformed at an unprecedented pace. During Installment 3 of the AccessSync 2026 Webinar Series, Accelerating Market Access: Overcoming Resource Delays, we brought together internal experts to discuss how access resources have evolved, what’s driving today’s compliance and timing challenges, and how technology—including AI—is reshaping the future of market access.
The panel featured Tracy Snyder and Maia Bobb, two AccessSync leaders whose combined experience spans nearly every phase of the market access lifecycle. What followed was an engaging discussion grounded in real-world experience and forward-looking strategy.
At its core, market access has always been about the same objective: bridging the gap between access barriers and patients. That bridge is built by pharma field teams, and their effectiveness depends heavily on the quality, clarity, and timing of the resources placed in their hands.
Historically, these resources looked very different than they do today. Early access teams relied on physical binders, printed leave-behinds, and in-person training sessions. Updates were slow. Distribution was manual. And any change, whether due to new data, labeling updates, or payer shifts, could take months to reach the field.
Over time, resources evolved alongside technology. Digital assets, virtual engagements, modular content, and centralized platforms replaced bulky binders and disconnected workflows. Yet while formats have modernized, the underlying pressure remains the same: teams must deliver compliant, impactful messaging fast.
As Tracy shared during the discussion, each major shift in market access resources has impacted not only creative execution, but the entire access pipeline, from strategy and review, to deployment and field adoption.
One of the most significant forces shaping today’s market access landscape is compliance and regulatory scrutiny. While compliance has always been part of the process, its role has expanded. Rather than acting solely as a final checkpoint, compliance now influences how resources are conceived, structured, and deployed from day one.
Maia highlighted that this shift has meaningfully changed how teams approach asset creation. Creativity still matters but it must operate within tighter guardrails. Messaging needs to be precise, adaptable, and defensible across a growing number of stakeholders, from payers to HCPs.
This heightened focus has also impacted timelines. Reviews are more complex. Feedback loops are longer. And the margin for error is smaller. That combination often results in delays that ripple across launch plans and field readiness.
Yet as Tracy emphasized, experience and process maturity make a difference. Teams that understand how to anticipate compliance needs and build them into workflows early are far better positioned to move quickly without sacrificing quality or confidence.
In market access, timing can be just as important as messaging. A perfectly designed resource that reaches the field too late can miss the moment entirely.
Panelists discussed how increasing complexity, more reviewers, more versions, more channels, has made speed-to-market one of the hardest challenges to solve. Even when teams are aligned, disconnected systems and manual handoffs can slow momentum.
The takeaway? Process efficiency matters as much as content quality. Delays are often less about effort and more about infrastructure.
No conversation about the future of pharma would be complete without addressing AI.
While AI adoption in market access is still evolving, its potential is undeniable. Panelists noted early impacts in areas such as content optimization, versioning, and process automation, particularly around administrative tasks that traditionally consume significant time and resources.
Importantly, AI isn’t positioned as a replacement for human expertise. Instead, it’s an accelerator that’s helping teams spend less time navigating logistics and more time focused on strategy, insight, and execution.
There was also thoughtful discussion around AI’s future role in compliance. As regulations continue to evolve, AI-powered tools may eventually help flag risk earlier, standardize reviews, and bring greater consistency to an increasingly complex process.
As the discussion wrapped, a few clear challenges emerged:
Navigating these challenges requires more than incremental fixes. It demands connected systems, smarter workflows, and partners who understand the realities of market access, not just in theory, but in practice.
What made this panel especially powerful was its authenticity. Tracy and Maia didn’t just talk about trends, they shared lived experiences, lessons learned, and the mindset required to keep moving forward.
Market access may be evolving faster than ever, but one thing remains constant: when teams are empowered with the right tools, at the right time, patients win.
We’re incredibly grateful to Tracy and Maia for their insights and to everyone who joined us for this conversation.
If today’s challenges resonated with your team, we invite you to continue the discussion and explore how AccessSync is helping organizations accelerate access, reduce delays, and move with confidence into 2026 and beyond.
Get the strategies your peers are using to close the gap between market access strategy and field execution. Join us live for our next webinar, “Asembia 2026: A Practical Guide for Access Leaders”, on April 9 at 1pm EST. Come ready with your toughest questions. Register now.
Discover how AccessSync customers are turning coverage data into confident HCP conversations — in a 30-minute demo tailored to your brand. Schedule your demo.
Stay current with the latest Access Realization™ insights.